Bill's Feed
Jan 8, 2013

Regeneron sees 2013 U.S. sales of Eylea up to $1.3 bln

Jan 8 (Reuters) – Regeneron Pharmaceuticals Inc on
Tuesday forecast U.S. sales of its fast-growing eye drug, Eylea,
of $1.2 billion to $1.3 billion in 2013.

Wall Street was disappointed by the initial sales outlook,
sending Regeneron’s high-flying shares down 5 percent.
Regeneron’s share price more than tripled in 2012 as the U.S.
biotechnology company repeatedly raised its Eylea sales forecast
over the course of the year.

Jan 4, 2013

Eli Lilly banks on cost controls for higher 2013 profit

By Bill Berkrot and Caroline Humer

(Reuters) – Eli Lilly and Co said on Friday it expects profit in 2013 to increase by more than Wall Street had been forecasting, primarily due to cost controls and improved productivity.

Lilly, whose shares were up nearly 4 percent on Friday, said 2013 sales will be flat to a bit higher, despite the loss of patent on its $5 billion-a-year antidepressant, Cymbalta, in December.

Jan 3, 2013

Biogen Lou Gehrig’s disease drug fails in key trial

By Bill Berkrot

(Reuters) – An experimental drug to combat amyotrophic lateral sclerosis, commonly called Lou Gehrig’s disease in the United States, failed to work in an important trial and Biogen Idec said it would stop development of the treatment.

The drug, dexpramipexole, had shown promise and seemed to work against ALS in a mid-stage clinical trial in 2011, creating hope for patients suffering from the progressive, fatal disease, who currently have few options.

Dec 20, 2012

Potentially game changing data awaits Acorda in 2013

NEW YORK (Reuters) – Acorda Therapeutics Inc Chief Executive Ron Cohen is already looking to spring, when data on a new use for its lone product could spur renewed investor interest and provide funding to enable his company to develop even more therapies.

The 2010 approval of Ampyra to improve walking in multiple sclerosis patients turned Acorda into a profitable company last year. If the drug can also help stroke victims who have suffered long term disability, it would open a large new market for Ampyra.

Dec 18, 2012

First funerals for Newtown victims as U.S. schools confront tragedy

, Dec 17 (Reuters) – One boy was
buried in his hero’s football jersey in a small white coffin.
Balloons and a teddy bear welcomed mourners to the funeral of
his first grade schoolmate.

The two funerals on Monday ushered in what will be a week of
memorial services and burials for the 20 children and six adults
massacred at Sandy Hook Elementary School in Newtown,
Connecticut.

Dec 18, 2012

Funerals begin in Newtown as schools confront tragedy

FAIRFIELD/NEWTOWN, Connecticut (Reuters) – One boy was buried in his hero’s football jersey in a small white coffin. Balloons and a teddy bear welcomed mourners to the funeral of his first grade schoolmate.

The two funerals on Monday ushered in what will be a week of memorial services and burials for the 20 children and six adults massacred at Sandy Hook Elementary School in Newtown, Connecticut.

Dec 17, 2012

Funerals begin for Newtown victims as schools confront tragedy

FAIRFIELD/NEWTOWN, Connecticut (Reuters) – One boy was buried in his hero’s football jersey in a small white coffin. Balloons and a teddy bear welcomed mourners to the funeral of his first grade schoolmate.

The two funerals on Monday ushered in what will be a week of memorial services and burials for the 20 children and six adults massacred at Sandy Hook Elementary School in Newtown, Connecticut.

Dec 11, 2012

Teva CEO promises to reshape, refocus company by 2017

NEW YORK, Dec 11 (Reuters) – Teva Pharmaceutical Industries’
new Chief Executive Jeremy Levin promised on
Tuesday to reshape the company into “the most indispensable
medicines company in the world” and to provide significant value
to its shareholders along the way.

At a meeting in New York with investors and analysts Levin,
who took over as CEO in May, said Teva would sustain “profitable
growth” through 2017 and beyond despite numerous challenges,
such as the looming 2015 patent expiration of its most important
branded product, the multiple sclerosis drug Copaxone. It
accounts for about 20 percent of Teva sales and an even higher
percentage of its profits.

Dec 8, 2012

Pfizer/Bristol drug cuts recurrence of blood clots – study

By Bill Berkrot

(Reuters) – A new blood clot preventer from Pfizer Inc and Bristol-Myers Squibb Co reduced the risk of recurrence of clots in veins and lungs and death by 80 percent with no increase in major bleeding in a study testing extended use of the drug.

In the year-long trial of 2,486 patients who had been previously treated for the condition known as venous thromboembolism (VTE) the drug, apixaban, met the combined primary goal by significantly reducing the recurrence of blood clots and death from any cause compared with a placebo, according to data presented at the American Society of Hematology (ASH) meeting in Atlanta, Georgia.

Dec 5, 2012

With Teva at crossroads, new CEO set to unveil vision

NEW YORK/TEL AVIV (Reuters) – Teva Pharmaceutical Industries’ new Chief Executive Jeremy Levin has promised investors it will be a very different company going forward. Next week he has to prove it.

Levin’s ability to paint a bright future for the world’s biggest maker of generic drugs at a meeting with investors and analysts on December 11 in New York became a bit more difficult last week, when Teva issued a 2013 earnings forecast that fell short of Wall Street estimates.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill